Metabolic disease is a signaling problem. The field is only starting to work on it that way.
For a century the field treated metabolism as arithmetic — intake against expenditure, a ledger the patient was expected to balance by will. The biology says otherwise. The body runs on messengers, and metabolic dysfunction is what happens when those messages degrade.
MetIQ exists to work at that layer. We build systems that support the body's own signaling, and we publish the mechanism behind them so the claim can be checked rather than believed.
What the inherited model gets wrong
Metabolism treated as arithmetic
Intake minus expenditure, with the person held responsible for the remainder. The model describes an outcome and explains none of the mechanism, which is why it fails the moment a body stops behaving like a ledger — and it has been failing for decades at population scale.
One receptor stands in for the axis
The category found a single effective target and built an entire market around it. GLP-1 became shorthand for metabolic signaling itself, while GIP and glucagon — carrying their own distinct jobs — went largely unaddressed in consumer formulation. The shorthand is now doing real damage to how people understand their own biology.
Signal loss framed as behavior
When messengers degrade, the visible result looks like appetite, energy, and discipline. So the failure gets attributed to the person rather than to the signaling that shaped their hunger and fatigue in the first place. That misattribution is the single most expensive error in the field.
Outcomes measured, mechanism ignored
Weight and glucose are endpoints — lagging, aggregate, and easy to move temporarily. The signaling that produced them is where the dysfunction actually lives, and where any durable change has to occur. Measuring only the endpoint rewards whatever moves it fastest.
Three shifts already underway
None of these is speculative. Each is visible in the published literature today, and each changes what a metabolic product is supposed to do — from moving one number to supporting the signaling that sets all of them. Read together, they point at the same conclusion: the axis, not the endpoint, is the unit of design.
From single targets to whole axes
Multi-receptor work is now outperforming single-target approaches in the published literature, and the gap widens as more of the axis is engaged. Coverage — not potency at one site — is becoming the design question. Three receptor families carry three different parts of the conversation, and a system that addresses one is answering a third of it.
From symptom control to signal restoration
Interest is moving upstream — toward mitochondrial signaling and the messengers that set metabolic tone, rather than the downstream numbers they produce. Support the signal and the numbers follow; chase the numbers and the signal stays degraded.
From population averages to individual readouts
Biomarker panels are getting cheap enough to make metabolic support specific to a person's signaling profile instead of their diagnosis category. The readouts are arriving faster than the products designed around them.
Where the work stands
Our research follows the thesis in two directions at once: the signaling itself, and the means of getting an active where a signal is needed. Each track has its own literature, its own methods, and its own timeline.
Both advance as the evidence supports the next step. Below, each track in its own terms.
GLP-III
A patent-pending, non-drug, non-stimulant system formulated to support signaling across all three incretin receptor families — GLP-1, GIP, and glucagon — rather than a single one.
The work sits at the formulation layer: which compounds, at which ratios, support signaling at each of the three sites without stimulant load. GLP-III is complete as designed and delivers its intended effect on its own — it depends on no carrier technology. We publish the mechanism in the Education Hub ahead of launch so the design intent can be read against the biology.
MOF carrier platform
Metal-organic framework research addressing two long-standing limits in oral delivery: how much of an active actually reaches circulation, and whether it can be directed to the cells that need it.
Bioavailability is the first problem — most orally delivered actives lose the majority of their payload before arriving anywhere useful. The second is specificity: a tunable porous carrier can hold an active and release it in response to local conditions, concentrating it at the tissue that needs it rather than distributing it broadly. It is a separate program from GLP-III, pursued on its own timeline, and the two are not dependent on one another.
Forward-looking research description. Nothing here is a clinical claim, a treatment recommendation, or a statement evaluated by the Food and Drug Administration.
Get the mechanism, not the marketing.
Launch dates, new articles, and Book Two progress. Roughly monthly, no drip sequences.
We send launch notices and new articles. No drip sequences.
Received — we'll be in touch.